09:36 AM EST - Tekmira Pharmaceuticals Corporation : announced today that, together with collaborators at The University of Texas Medical Branch, it has been awarded a new United States National Institutes of Health grant to support research to develop RNAi therapeutics to treat Ebola and Marburg hemorrhagic fever viral infections using Tekmira's lipid nanoparticle delivery technology. The grant, worth $2.4 million, will support work at Tekmira and the University of Texas Medical Branch at Galveston, Texas. Tekmira Pharmaceuticals Corporation
shares T.TKM are trading even at $1.25.
